Women's Health

The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.

What can we help you find?

Women in Pharmacy: Challenges, Successes, and Support

Attendees at the McKesson ideaShare had the chance to hear about women pharmacists and the challenges, successes, and opportunities they have in a session presented by Suzanne Soliman, PharmD.

New Treatment for HSDD Granted FDA Approval for Premenopausal Women

The effectiveness and safety of bremelanotide were studied in a pair of 24-week, randomized, double-blind, placebo-controlled trials in 1247 premenopausal women with acquired, generalized HSDD.

FDA Approves Drospirenone Tablet for Pregnancy Prevention

A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen.

Prescribing Contraceptives: Oregon Pharmacists Help the Medicaid Population

Contraceptives are both a popular and effective birth control method, and Medicaid fully covers them for its beneficiaries.

Multidisciplinary Approach Recommended for Management of Preexisting Diabetes in Pregnancy

Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.

Study: Racial Disparities Among Women with HIV

This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.

Hormone Therapy Combination Now Available for Treating Hot Flashes in Menopausal Women

The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use.

New Treatment for Osteoporosis In Postmenopausal Women is Available

Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

FDA Orders Safety Labeling Changes for Female Sexual Dysfunction Therapy

The action requires the company to revise safety information that women and their health care professionals need when considering use of the drug.

New Osteoporosis Therapy for Postmenopausal Women Granted FDA Approval

Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.

FDA Approves First Drug for Postpartum Depression

This therapy is expected to become available in late June.

Incorrect Tablet Arrangement Leads to Oral Contraceptive Recall

Indicating for preventing pregnancy, a statement from the FDA said that loss of efficacy is possible if the user misses tablets.

The Pharmacy Times® Women’s Health resource center page serves as a host for information about the most intricate questions surrounding women’s health issues.

Women have unique health issues, and some conditions and diseases that can be had by both sexes have the potential to impact women differently. Additionally, women should be keeping tabs on pregnancy, menopause, and conditions of the female organs; pharmacists can help. This resource center provides the latest clinical information, recent updates from a robust pipeline of novel therapies, and the newest data from all phases of clinical trials and studies in the space, allowing pharmacists to have an expert level of understanding of how to meet their customers’ needs.